Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 255

1.

The effect of raloxifene after discontinuation of long-term alendronate treatment of postmenopausal osteoporosis.

Michalsk√° D, Stepan JJ, Basson BR, Pavo I.

J Clin Endocrinol Metab. 2006 Mar;91(3):870-7. Epub 2005 Dec 13.

PMID:
16352692
2.

Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis.

Johnell O, Scheele WH, Lu Y, Reginster JY, Need AG, Seeman E.

J Clin Endocrinol Metab. 2002 Mar;87(3):985-92.

3.

Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension.

Ensrud KE, Barrett-Connor EL, Schwartz A, Santora AC, Bauer DC, Suryawanshi S, Feldstein A, Haskell WL, Hochberg MC, Torner JC, Lombardi A, Black DM; Fracture Intervention Trial Long-Term Extension Research Group.

J Bone Miner Res. 2004 Aug;19(8):1259-69. Epub 2004 Mar 29.

4.

Effects of teriparatide in postmenopausal women with osteoporosis on prior alendronate or raloxifene: differences between stopping and continuing the antiresorptive agent.

Cosman F, Wermers RA, Recknor C, Mauck KF, Xie L, Glass EV, Krege JH.

J Clin Endocrinol Metab. 2009 Oct;94(10):3772-80. doi: 10.1210/jc.2008-2719. Epub 2009 Jul 7.

PMID:
19584192
5.

Overlapping and continued alendronate or raloxifene administration in patients on teriparatide: effects on areal and volumetric bone mineral density--the CONFORS Study.

Muschitz C, Kocijan R, Fahrleitner-Pammer A, Pavo I, Haschka J, Schima W, Kapiotis S, Resch H.

J Bone Miner Res. 2014 Aug;29(8):1777-85. doi: 10.1002/jbmr.2216.

6.
7.

Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women.

Murphy MG, Weiss S, McClung M, Schnitzer T, Cerchio K, Connor J, Krupa D, Gertz BJ; MK-677/Alendronate Study Group.

J Clin Endocrinol Metab. 2001 Mar;86(3):1116-25.

PMID:
11238495
8.
9.

Effect of low-dose alendronate treatment on bone mineral density and bone turnover markers in Chinese postmenopausal women with osteopenia and osteoporosis.

Li M, Zhang ZL, Liao EY, Chen DC, Liu J, Tao TZ, Wu W, Xia WB, Lu YJ, Sheng ZF, Lu CY, Meng GL, Xu L, Zhang WJ, Hu YY, Xu L.

Menopause. 2013 Jan;20(1):72-8. doi: 10.1097/gme.0b013e31825fe2e8.

PMID:
22968256
10.

Treatment with alendronate plus calcium, alendronate alone, or calcium alone for postmenopausal low bone mineral density.

Bonnick S, Broy S, Kaiser F, Teutsch C, Rosenberg E, DeLucca P, Melton M.

Curr Med Res Opin. 2007 Jun;23(6):1341-9.

PMID:
17594775
11.

Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results from a 6-month double-blind placebo-controlled trial.

Deal C, Omizo M, Schwartz EN, Eriksen EF, Cantor P, Wang J, Glass EV, Myers SL, Krege JH.

J Bone Miner Res. 2005 Nov;20(11):1905-11. Epub 2005 Jul 18.

12.

Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial.

Black DM, Schwartz AV, Ensrud KE, Cauley JA, Levis S, Quandt SA, Satterfield S, Wallace RB, Bauer DC, Palermo L, Wehren LE, Lombardi A, Santora AC, Cummings SR; FLEX Research Group.

JAMA. 2006 Dec 27;296(24):2927-38.

PMID:
17190893
13.

Effects of odanacatib on BMD and safety in the treatment of osteoporosis in postmenopausal women previously treated with alendronate: a randomized placebo-controlled trial.

Bonnick S, De Villiers T, Odio A, Palacios S, Chapurlat R, DaSilva C, Scott BB, Le Bailly De Tilleghem C, Leung AT, Gurner D.

J Clin Endocrinol Metab. 2013 Dec;98(12):4727-35. doi: 10.1210/jc.2013-2020. Epub 2013 Sep 24.

PMID:
24064689
14.

Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis. A randomized, double-blind, placebo-controlled trial.

Greenspan SL, Emkey RD, Bone HG, Weiss SR, Bell NH, Downs RW, McKeever C, Miller SS, Davidson M, Bolognese MA, Mulloy AL, Heyden N, Wu M, Kaur A, Lombardi A.

Ann Intern Med. 2002 Dec 3;137(11):875-83.

PMID:
12458987
15.

Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass.

Bone HG, Bolognese MA, Yuen CK, Kendler DL, Miller PD, Yang YC, Grazette L, San Martin J, Gallagher JC.

J Clin Endocrinol Metab. 2011 Apr;96(4):972-80. doi: 10.1210/jc.2010-1502. Epub 2011 Feb 2.

PMID:
21289258
16.

Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate.

Ettinger B, San Martin J, Crans G, Pavo I.

J Bone Miner Res. 2004 May;19(5):745-51. Epub 2004 Jan 19.

17.

Raloxifene for prevention of glucocorticoid-induced bone loss: a 12-month randomised double-blinded placebo-controlled trial.

Mok CC, Ying KY, To CH, Ho LY, Yu KL, Lee HK, Ma KM.

Ann Rheum Dis. 2011 May;70(5):778-84. doi: 10.1136/ard.2010.143453. Epub 2010 Dec 27.

PMID:
21187295
18.

Efficacy and tolerability of once-monthly oral ibandronate (150 mg) and once-weekly oral alendronate (70 mg): additional results from the Monthly Oral Therapy With Ibandronate For Osteoporosis Intervention (MOTION) study.

Emkey R, Delmas PD, Bolognese M, Borges JL, Cosman F, Ragi-Eis S, Recknor C, Zerbini CA, Neate C, Sedarati F, Epstein S.

Clin Ther. 2009 Apr;31(4):751-61. doi: 10.1016/j.clinthera.2009.04.018.

PMID:
19446148
19.

Changes in bone markers after once-weekly low-dose alendronate in postmenopausal women with moderate bone loss.

Choi HJ, Im JA, Kim SH.

Maturitas. 2008 Jun 20;60(2):170-6. doi: 10.1016/j.maturitas.2008.05.003. Epub 2008 Jun 24.

PMID:
18572334
20.

Increments in bone mineral density of the lumbar spine and hip and suppression of bone turnover are maintained after discontinuation of alendronate in postmenopausal women.

Stock JL, Bell NH, Chesnut CH 3rd, Ensrud KE, Genant HK, Harris ST, McClung MR, Singer FR, Yood RA, Pryor-Tillotson S, Wei L, Santora AC 2nd.

Am J Med. 1997 Oct;103(4):291-7.

PMID:
9382121

Supplemental Content

Support Center